ArticleAnnals of medicine2025
Identification of GBP6 as a potential prognostic biomarker in esophageal carcinoma by integrated bioinformatics analysis and experiment validation.
Article in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Guanylate-binding protein 2 (GBP2) drives pancreatic cancer cell proliferation by promoting cell cycle progression via the SP1/SKP2/P27 axis.Journal of translational medicine · 2026Article
- Th2 Cytokines Reshape the Transcriptome: Insights from a Canine Organoid Model of Atopic Dermatitis.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundsTo evaluate the role of guanylate-binding protein 6 (GBP6) in esophageal cancer (ESCA).
methodsWe comprehensively evaluated the expression pattern, clinical features, prognostic role, biological functions, and immunological role of GBP6 based on the public databases. Immunohistochemistry was used to validate the results in an ESCA tissue microarray. The proliferative activity of ESCA cells was evaluated using cell counting kit 8 assay. The cell cycle changes were determined using flow cytometry. We also analyzed potential compounds for combination therapy with GBP6.
resultsAmong the GBPs family, we found that GBP6 was only specifically expressed in the normal oropharyngeal tract, while its expression was downregulated in ESCA tissues. Patients with low expression of GBP6 was associated with poor prognosis, worse grade and TNM stage. However, no significant relationship between GBP6 and the immune microenvironment in ESCA. Enrichment analysis showed that GBP2-high expression group was significantly enriched in the p53 signaling pathway. Then, we found that knockdown of GBP6 expression inhibited the proliferative of ESCA cells and induced the cell cycle arrest. Moreover, the expression of p53, p21, and p27 were also downregulated in the GBP6 knockdown group. Finally, drug response prediction revealed that several small molecule compounds may have better anti-cancer effects in samples with high expression of GBP6.
conclusionThe GBP6 could be a potential prognostic therapeutic target for ESCA treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.